Feasibility of computerized motor, cognitive and speech tests in the home: Analysis of TAS Test in 2,300 older adults - 27/03/25
, Renjie Li a , Eddy Roccati a , Katherine Lawler a, b , Aidan Bindoff a , Anna King a , James Vickers a , Quan Bai c , Jane Alty a, d, ⁎
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Background |
Early detection of Alzheimer's disease (AD) risk is crucial for dementia prevention. Tasmanian Test (TAS Test) is a novel, unsupervised, computerized assessment of motor, cognitive, and speech function designed to detect AD risk.
Objectives |
To evaluate the feasibility, usability, and acceptability of TAS Test.
Design and setting |
TAS Test was administered remotely at home and/or in a research facility, using personal computers.
Participants |
2,351 adults aged 50–89 years (mean 65.35), 71.76 % female, from Tasmania, Australia.
Measurements |
Completion rates, ease-of-use, distraction, test duration, and enjoyment scores. Demographics, computer literacy, cognition, and mood were analyzed.
Results |
Over 80 % completed motor and cognitive components with 92.8 % completing speech tests. 89.81 % found the duration acceptable. 80.90 % of remote and 83.46 % of onsite participants enjoyed the procedure. High usability and acceptability were reported, with age, gender, education, computer literacy, cognition and mood having minimal or no impact.
Conclusions |
TAS Test demonstrated high completion rates and user satisfaction across a large community sample, supporting its feasibility as an unsupervised computerized assessment tool. Future research should address demographic representation and technical refinements.
El texto completo de este artículo está disponible en PDF.Keywords : TAS Test, ISLAND, Digital biomarker, Dementia, Artificial intelligence
Esquema
Vol 12 - N° 4
Artículo 100081- avril 2025 Regresar al número
Artículo precedente
- Characterizing and validating 12-month reliable cognitive change in Early-Onset Alzheimer's Disease for use in clinical trials
- Dustin B. Hammers, Jane Musema, Ani Eloyan, Maryanne Thangarajah, Alexander Taurone, Renaud La Joie, Alexandra Touroutoglou, Prashanthi Vemuri, Joel Kramer, Paul Aisen, Jeffrey L. Dage, Kelly N. Nudelman, Kala Kirby, Alireza Atri, David Clark, Gregory S. Day, Ranjan Duara, Neill R. Graff-Radford, Ian Grant, Lawrence S. Honig, Erik C.B. Johnson, David T. Jones, Joseph C. Masdeu, Mario F. Mendez, Kyle Womack, Erik Musiek, Chiadi U. Onyike, Meghan Riddle, Emily Rogalski, Steven Salloway, Sharon J. Sha, Raymond Scott Turner, Thomas S. Wingo, David A. Wolk, Maria C. Carrillo, Gil D. Rabinovici, Bradford C. Dickerson, Liana G. Apostolova, the LEADS Consortium
- Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease
- Erika N. Cline, Daniel Antwi-Berko, Karen Sundell, Elizabeth Johnson, Maddelyn Hyland, Hao Zhang, Hugo Vanderstichele, June Kaplow, Robert A. Dean, Erik Stoops, Eugeen Vanmechelen, Marleen J.A. Koel-Simmelink, Charlotte E. Teunissen, Gopalan Sethuraman, Todd Feaster, Eric Siemers, Jasna Jerecic
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.